Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
作者信息
Ngelangel C A, Jimenez M V, Villalon A H, Agustin B M
出版信息
Southeast Asian J Trop Med Public Health. 1985 Dec;16(4):634-7.
PMID:2940689
Abstract
The efficacy and tolerability of the combined scheme of administering high dose medroxyprogesterone acetate in advanced breast cancer is evaluated.
摘要
相似文献
1
Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Southeast Asian J Trop Med Public Health. 1985 Dec;16(4):634-7.
2
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Chemioterapia. 1987 Dec;6(6):396-8.
3
Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
Chemioterapia. 1984 Oct;3(5):320-3.
4
5
6
Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Cancer Treat Rep. 1987 Sep;71(9):813-5.
7
[Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Gan To Kagaku Ryoho. 1982 Nov;9(11):1994-2004.
8
Current status of high dose progestin treatment in advanced breast cancer.大剂量孕激素治疗晚期乳腺癌的现状
Breast Cancer Res Treat. 1983;3(2):231-5. doi: 10.1007/BF01803566.
9
10
[Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
Hinyokika Kiyo. 1989 Apr;35(4):603-8.
Zotero 插件